Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adefovir-related nephrotoxicity by adefovir dose-reduction in HBV

A study in the latest issue of Alimentary Pharmacology & Therapeutics investigates resolution of adefovir-related nephrotoxicity by adefovir dose-reduction in patients with chronic hepatitis B.

News image

Chronic hepatitis B patients treated with adefovir were followed up to evaluate nephrotoxicity and its outcome.

Dr Hartono and colleagues assessed the incidence of renal dysfunction during adefovir therapy in Asian patients and factors associated with it.

The team evaluated strategies to improve adefovir-related renal dysfunction, and their impact on viral suppression.

The researchers evaluated chronic hepatitis B clinic patients from a tertiary hospital on adefovir treatment.

The team extracted clinical and laboratory parameters from the hospital electronic clinical database in an observational study design.

Patients were excluded if they had liver/renal transplant, baseline renal impairment or were on dialysis.

The team of doctors defined adefovir-related renal dysfunction as adefovir-related abnormal serum creatinine as 125 μmol/L, 90 μmol/L for adefovir-related abnormal GFR 60 mL/min, and adefovir-related increased serum creatinine as 0.5 mg/dL, without other known causes of nephrotoxicity.

A total of 271 out of 383 adefovir-treated patients were suitable for analysis, and 33 patients developed abnormal serum creatinine.

Adefovir-related abnormal serum creatinine was 34%
Alimentary Pharmacology & Therapeutics

The research team found that cumulative increase in proportion of patients with adefovir-related abnormal serum creatinine was 34% and adefovir-related abnormal 60 mL/min was 38% by 6 years, while serum creatinine increase 0.5 mg/dL was 22% by 5 years.

Using multivariate analysis, the only independent baseline predictor of adefovir-related abnormal serum creatinine was adefovir-related abnormal 76.1 mL/min.

The team of doctors noted that patients who had adefovir-related abnormal serum creatinine had similar levels of viral suppression to those who did not have adefovir-related abnormal serum creatinine.

Those who had adefovir-related abnormal serum creatinine either continued adefovir, switched therapy or had adefovir dose reduction.

The researchers reported that adefovir-related abnormal serum creatinine resolved and adefovir-related abnormal normalised in almost all patients after either switching therapy or reducing adefovir dose, with no difference between the two strategies.

Those with adefovir dose reduction had no significant increase in HBV DNA.

Dr Hartono and his team commented, "Adefovir-related renal dysfunction occurred in a significant number of adefovir-treated patients, but reduction of the dose led to renal improvement without compromising treatment efficacy."

Aliment Pharmacol Ther 2013
04 March 2013

Go to top of page Email this page Email this page to a colleague

 23 April 2014

Advanced search
 23 April 2014 
Colorectal cancer risk in MUTYH mutation carriers
 23 April 2014 
Fecal microbiota transplantation therapy
 23 April 2014 
Cancer risk after resection of polypoid dysplasia
 22 April 2014 
Endoscopy guidelines to select patients for colonoscopy
 22 April 2014 
PPI use and cancer in Barrett's
 22 April 2014 
Ledipasvir and sofosbuvir for HCV genotype 1
 17 April 2014 
Screening for low bone mineral density among ulcerative colitis
 17 April 2014 
Diabetes mellitus and acute pancreatitis
 17 April 2014 
Bowel cleansing for colonoscopy
 16 April 2014 
Evaluating pharmacologic agents in IBS
 16 April 2014 
Isotretinoin and IBD risk
 16 April 2014 
Mortality in bleeding Mallory-Weiss syndrome vs peptic ulcer bleeding
 15 April 2014 
Dietary fat and risk of IBD
 15 April 2014 
Quality of life in microscopic colitis
 15 April 2014 
New prognostic score for cirrhosis
 14 April 2014 

5-aminosalicylates in early pregnancy and congenital malformation risk

 14 April 2014 
Changing liver cancer mortality rates in the United States
 14 April 2014 
Inflammatory sacroiliitis by MRI in IBD
 11 April 2014 
H pylori resistance to antibiotics
 11 April 2014 
Predictors of corticosteroid treatment outcomes for ulcerative colitis
 11 April 2014 
Antibiotic combination therapy for ulcerative colitis
 10 April 2014 
Mortality in Crohn's disease
 10 April 2014 
Prophylaxis against venous thromboembolism in hospitalized ulcerative colitis
 10 April 2014 
Probiotic treatment and infant colic
 09 April 2014 
Preventing death in general intensive care
 09 April 2014 
Neoplasm risk after polypectomy
 09 April 2014 
Disclosure program and gastroenterology-related claims
 08 April 2014 

Regurgitation and health-related quality of life in GERD

 08 April 2014 
H. pylori resistance to antibiotics
 08 April 2014 
Management of chronic diarrhea
 07 April 2014 
Gastrointestinal angiodysplastic lesions
 07 April 2014 
Meat intake and liver cancer
 07 April 2014 
Adenoma detection and colorectal cancer risk
 04 April 2014 
Stool DNA tests for colorectal cancer
 04 April 2014 
PET-CT predicts outcome in colorectal liver metastases
 04 April 2014 

Prophylaxis of post-ERCP pancreatitis

 03 April 2014 
Management of esophageal or gastric variceal bleeding
 03 April 2014 
Exclusionary diets for IBD
 03 April 2014 
Mortality with chronic pancreatitis
 02 April 2014 
Disease course of early-onset pediatric IBD
 02 April 2014 
Risk of liver fibrosis progression in chronic hep B
 02 April 2014 
Colorectal cancer and patient survival
 01 April 2014 
Outcomes in patients with Hep C
 01 April 2014 
Diagnosis of functional dyspepsia
 01 April 2014 
Genetic risk factors for stenosis and infections in primary sclerosing cholangitis
 31 March 2014 
Diet-gene interactions and Crohn's
 31 March 2014 
Transjugular intrahepatic portosystemic stent-shunts in Budd–Chiari syndrome
 31 March 2014 
Hepatic decompensation in antiretroviral-treated patients
 28 March 2014 
Glucocorticoids and mortality after colorectal cancer surgery
 28 March 2014 
Long-term metformin use and gastric cancer risk
 28 March 2014 
Distance from a liver transplant center and survival
 27 March 2014 
Radiofrequency ablation vs endoscopy for Barrett's
 27 March 2014 
Omega-3 fatty acid and Crohn's disease
 27 March 2014 
Thromboembolism prophylaxis in IBD
 26 March 2014 
Disparities in evaluation of rectal bleeding
 26 March 2014 
Prediction of H. pylori status after endoscopy
 26 March 2014 
Fatigue and depression in IBD
 25 March 2014 
Depression risk in IBD
 25 March 2014 
Fecal incontinence in the USA
 25 March 2014 
Circulating gastrin and colorectal carcinoma risk

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us